Furthermore, several liver-targeting HDAC inhibitors potently suppress HCC growth and animal and preclinical studies with HDAC inhibitors suggest survival benefits (Yeo et al., 2012; Afaloniati et al., 2020; Tapadar et al., 2020). This evidence concerns the gene HDAC9 and hepatocellular carcinoma.